Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

ClinicalTrials.gov ID: NCT06358950

Public ClinicalTrials.gov record NCT06358950. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1

Study identification

NCT ID
NCT06358950
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
92 participants

Conditions and interventions

Interventions

  • ALKS 2680 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 23, 2024
Primary completion
Jun 18, 2025
Completion
Jul 30, 2025
Last update posted
Jun 9, 2026

2024 – 2025

United States locations

U.S. sites
29
U.S. states
13
U.S. cities
27
Facility City State ZIP Site status
Alkermes Investigational Site Los Angeles California 90025
Alkermes Investigational Site Redwood City California 94063
Alkermes Investigator Site San Francisco California 94107
Alkermes Investigational Site Santa Ana California 92705
Alkermes Investigational Site Aurora Colorado 80045
Alkermes Investigational Site Colorado Springs Colorado 80918
Alkermes Investigational Site Brandon Florida 33511
Alkermes Investigator Site Brandon Florida 33511
Alkermes Investigational Site Miami Florida 33176
Alkermes Investigator Site Winter Park Florida 32789
Alkermes Investigational Site Atlanta Georgia 30328
Alkermes Investigational Site Macon Georgia 31210
Alkermes Investigational Site Stockbridge Georgia 30281
Alkermes Investigator Site Peoria Illinois 61637
Alkermes Investigator Site Lansing Michigan 48911
Alkermes Investigator Site Sterling Heights Michigan 48314
Alkermes Investigator Site Lincoln Nebraska 68506
Alkermes Investigational Site Middletown New Jersey 07748
Alkermes Investigational Site Denver North Carolina 28037
Alkermes Investigational Site Huntersville North Carolina 28708
Alkermes Investigator Site Canton Ohio 44718
Alkermes Investigational Site Cincinnati Ohio 45227
Alkermes Investigational Site Cincinnati Ohio 45245
Alkermes Investigational Site Dublin Ohio 43017
Alkermes Investigational Site Wyomissing Pennsylvania 19610
Alkermes Investigational Site Columbia South Carolina 29201
Alkermes Investigational Site Austin Texas 78731
Alkermes Investigational Site San Antonio Texas 78229
Alkermes Investigational Site The Woodlands Texas 77380

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06358950, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 9, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06358950 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →